VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: j g cordes who wrote (5)	5/12/1999 5:29:00 AM
From: glen	Read Replies (1) of 250

I believe it will go to a premium after the IPO, but it is much too early to even predict. Indications by Prudential has not even begun yet. Genentech put in around $50 million between 1985 and 1995 before spinning VaxGen off as a separate company. They still have a 25% interest. At this point in time, there is no cure for AIDS. VaxGen is two years ahead of any other group or company testing or developing an AIDS vaccine. VaxGen has had positive results in its Phase II Clinical trials. I believe VaxGen currently has $20 million in cash, in addition to an already existing vaccine. Of course, this vaccine has a while to go before it can even be approved by the FDA. But, there are biotech companies with much less than VaxGen has which which trade at premiums. In my analysis, this is a company with great potential and worth following, let alone investing in. Remember that vaccines are preventative and the market for this is tremendous. It will be a multi-billion dollar market, and if VaxGen is successful, they will have the market to themselves. What do you think the stock will do?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next